Top View
- Pharmacology Review(S)
- Imatinib Resistance and Microcytic Erythrocytosis in a Kit Gatekeeper-Mutant Mouse Model of Gastrointestinal Stromal Tumor
- Nexavar, INN-Sorafenib
- Trastuzumab Emtansine Is Active on HER-2 Overexpressing NSCLC Cell
- Molecular Targeting of HER2-Overexpressing Biliary Tract Cancer Cells with Trastuzumab Emtansine, an Antibody–Cytotoxic Drug Conjugate
- Evaluation of the KIT/Stem Cell Factor Axis in Renal Tumours
- Qtc Interval Prolongation with Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors
- Metformin Reverses Stem Cell‑Like Hepg2 Sphere Formation and Resistance to Sorafenib by Attenuating Epithelial‑Mesenchymal Transformation
- New Knowledge of the Mechanisms of Sorafenib Resistance in Liver Cancer
- Sorafenib and Sunitinib in Renal Cell Carcinoma Mark N
- NEXAVAR (Sorafenib) Tablets, for Oral Use QT Prolongation: Monitor Electrocardiograms and Electrolytes in Initial U.S
- Adult Antiemetic Management of Chemotherapy-Induced Nausea
- Assessment of Vitamin D Levels in Newly Diagnosed Breast Cancer
- Lenvatinib (Lenvima™), Pazopanib (Votrient®), Sorafenib (Nexavar®) EOCCO POLICY Policy Type: PA/SP Pharmacy Coverage Policy: EOCCO166
- Pazopanib in Renal Cell Carcinoma
- Efficacy and Safety of Sorafenib Versus Sunitinib As First-Line Treatment in Patients with Metastatic Renal Cell Carcinoma
- Sorafenib Inhibits Imatinib-Resistant KIT and Platelet-Derived Growth
- Highlights from ASCO-GI 2021 from EORTC Gastrointestinal Tract Cancer Group ✉ Thibaud Koessler 1,2,3 , Maria Alsina3,4, Dirk Arnold3,5, Irit Ben-Aharon3,6, Manfred P